F S&P 500
5,714.75 +94.00 (+1.67%) F Dow Jones
42,019.00 +493.00 (+1.19%) F Nasdaq
19,763.25 +414.00 (+2.14%) E-mini Russell 2000 Index Futur
2,303.60 +73.70 (+3.31%) Petróleo
71.35 +0.44 (+0.62%) Oro
2,613.10 +14.50 (+0.56%)
Oxford BioDynamics Plc (OXBOF)
Oxford BioDynamics Plc
3140 Rowan Place
John Smith Drive Oxford Business Park South
Oxford OX4 2WB
United Kingdom
44 1865 518 910
https://www.oxfordbiodynamics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 53
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. | CEO & Executive Director | 803.31k | N/D | 1962 |
| Mr. Paul Leslie Stockdale F.C.A., M.A. | CFO & Executive Director | 316.82k | N/D | 1975 |
| Dr. Alexandre Akoulitchev M.A., Ma (Oxon), Ph.D. | Chief Scientific Officer & Executive Director | 365.87k | N/D | 1962 |
| Mr. Thomas G. Guiel B.A. | Chief Operating Officer | N/D | N/D | N/D |
| David Blum | Senior Vice President of Marketing | N/D | N/D | N/D |
| Dr. Steven Arrivo | Senior Vice President of Business & Corporate Development | N/D | N/D | N/D |
| Dr. Ewan Hunter B.Sc., Ph.D., Ph.D., (KCL) | Chief Data Officer | N/D | N/D | N/D |
| T. Demain | Company Secretary | N/D | N/D | N/D |
Descripción
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Gestión corporativa
La calificación ISS Governance QuickScore de Oxford BioDynamics Plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
